[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
August 9, 1985

Double-blind as a BHAT

Author Affiliations

University of Massachusetts Medical School Worcester

JAMA. 1985;254(6):755. doi:10.1001/jama.1985.03360060053019

To the Editor.—  In assessing the "double-blindness" of the β-Blocker Heart Attack Trial, Byington and colleagues1 have contributed an important set of observations. Their importance is magnified by the perceptive and well-written editorial of Dr Morgan.2 The next question that the authors may wish to deal with is: What were the results in those patients receiving placebo who believed they were on a drug regimen in comparison with the others receiving placebo and with those receiving drug? (Other potential subgroup comparisons are obvious.) The statistics on their outcomes must be readily available to the authors and, if significant differences can be exposed, would further affect the overall interpretation of the trial results.